Granules India Limited (GRANULES) announced potential first-to-file status for its Ruxolitinib Extended-Release Tablets ANDA, aiming for 180 days of generic.
Granules India Limited (GRANULES) secures Sole First-to-File status for its ANDA for Sodium Oxybate Extended-Release for Oral Suspension.